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Triclosan (5-chloro-2-(2,4-dichlorophenoxy)-phenol) is a chlori-
nated phenolic antibacterial compound found in consumer
products. In vitro human pregnane X receptor activation, hepatic
phase I enzyme induction, and decreased in vivo total thyroxine
(T4) suggest adverse effects on thyroid hormone homeostasis.
Current research tested the hypothesis that triclosan decreases
circulating T4 via upregulation of hepatic catabolism and trans-
port. Weanling female Long-Evans rats received triclosan (0–1000
mg/kg/day) by gavage for 4 days. Whole blood and liver were
collected 24 h later. Total serum T4, triiodothyronine (T3), and
thyroid-stimulating hormone (TSH) were measured by radioim-
munoassay. Hepatic microsomal assays measured ethoxyresorufin-
O-deethylase, pentoxyresorufin-O-deethylase (PROD), and uridine
diphosphate glucuronyltransferase enzyme activities. The messen-
ger RNA (mRNA) expression of cytochrome P450s 1a1, 2b1/2, and
3a1/23; UGTs 1a1, 1a6, and 2b5; sulfotransferases 1c1 and 1b1;
and hepatic transporters Oatp1a1, Oatp1a4, Mrp2, and Mdr1b was
measured by quantitative reverse transcriptase PCR. Total T4
decreased dose responsively, down to 43% of control at 1000 mg/
kg/day. Total T3 was decreased to 89 and 75% of control at
300 and 1000 mg/kg/day. TSH did not change. Triclosan dose
dependently increased PROD activity up to 900% of control at
1000 mg/kg/day. T4 glucuronidation increased nearly twofold at
1000 mg/kg/day. Cyp2b1/2 and Cyp3a1/23 mRNA expression levels
were induced twofold and fourfold at 300 mg/kg/day. Ugt1a1 and
Sult1c1 mRNA expression levels increased 2.2-fold and 2.6-fold
at 300 mg/kg/day. Transporter mRNA expression levels were
unchanged. These data denote important key events in the mode of
action for triclosan-induced hypothyroxinemia in rats and suggest
that this effect may be partially due to upregulation of hepatic
catabolism but not due to mRNA expression changes in the tested
hepatic transporters.
Key Words: mode of action; triclosan; thyroid disruption;
glucuronyltransferase; sulfotransferase; hepatic transport.
Triclosan is a chlorinated phenolic bacteriocide used as an
active ingredient in personal care products, including soaps,
toothpastes, toys, and clothing (Bhargava & Leonard, 1996;
Dayan, 2007; McClanahan & Bartizek, 2002). Due to broad use,
environmental fate, and transport, triclosan is an environmental
contaminant (Kolpin et al., 2002; Paxeus, 1996). Triclosan
contamination of effluents is one of several potential sources for
human exposure, along with personal care product exposure
(Allmyr et al., 2006; Sandborgh-Englund et al., 2006).
Triclosan is readily absorbed from the gastrointestinal tract
and oral mucosa (Sandborgh-Englund et al., 2006). Triclosan
has been detected in human breast milk, at levels ranging from
0 to 2100 lg/kg lipid (Adolfsson-Erici et al., 2002; Allmyr
et al., 2006; Dayan, 2007), in serum (Allmyr et al., 2006;
Hovander et al., 2002) and as triclosan metabolites in urine
(Calafat et al., 2008; Wolff et al., 2007). These data demonstrate
exposure in humans and underscore the importance of using
models to assess any potential effects resulting from human
triclosan exposure.
Laboratory studies have documented that triclosan disrupts
thyroid systems in rats and frogs (Crofton et al., 2007;
Veldhoen et al., 2006; Zorrilla et al., 2009). In vitro evidence
also suggests that triclosan may be an antagonist (Ahn et al.,
2008; Gee et al., 2008) or weak agonist (Houtman et al., 2004)
of the estrogen receptor and/or a weak antagonist of the
androgen receptor (Chen et al., 2007).
Adverse effects of triclosan on thyroid hormone (TH)
homeostasis have been reported in rats and frogs. Short-term
oral triclosan exposure resulted in hypothyroxinemia in
weanling rats (Crofton et al., 2007). Stoker and colleagues
reported that triclosan decreased T4 without significantly
affecting thyroid-stimulating hormone (TSH) following a 31-
day oral triclosan exposure (Zorrilla et al., 2009). Veldhoen
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et al. (2006) reported increased thyroid receptor b messenger
RNA (mRNA) expression in Xenopus laevis XTC-2 cells when
coexposed to T3 and accelerated hind limb development
in vivo in Rana catesbeiana. The mode of action for thyroid
disruption by triclosan is currently undefined.
Thyroid disruption may occur via several mechanisms,
including disruption of TH synthesis via inhibition of thyroper-
oxidase or iodide uptake, binding to TH transport proteins,
xenobiotic interactions with the TH receptor or TSH receptor,
upregulation of iodothyronine deiodinases, and increases in
TH clearance (Boas et al., 2006; Crofton, 2008, Capen, 1994).
Evidence suggests that triclosan may upregulate hepatic
catabolism of THs, a known key event in a mode of action
leading to decreased THs (Crofton, 2008; Crofton & Zoeller,
2005; Hill et al., 1998; McClain et al., 1989). The initiating
event in this mode of action is the activation of hepatic nuclear
receptors (Barter & Klaassen, 1994; Crofton & Zoeller, 2005;
Hill et al., 1998; Hood & Klaassen, 2000; McClain, 1989).
Nuclear receptors (pregnane X receptor [PXR] and constitutive
androstane receptor [CAR]) regulate hepatic catabolic and
transport activity (Kretschmer & Baldwin, 2005), suggesting
that potential agonism or antagonism of CAR/PXR results in
downstream metabolic changes that affect serum TH levels. In
PXR reporter assays, triclosan moderately activated human
PXR relative to the prototypical inducer, rifampicin (Jacobs
et al., 2005). Furthermore, triclosan increased Cyp2b1/2 and
Cyp3a1 protein and enzymatic activity markers of cytochrome
P450 (CYP) activity including pentoxyresorufin-O-deethylase
(PROD), benzyloxyresorufin-O-debentylase, and ethoxyresor-
ufin-O-deethylase (EROD) in hepatocytes in vitro and in
hepatic microsomes ex vivo (Hanioka et al., 1996; Jinno et al.,
1997; Zorrilla et al., 2009). Triclosan inhibited diiodothyronine
(T2) sulfotransferases in rat and human hepatocytes in vitro,
suggesting interference with TH sulfation (Wang & James,
2006; Wang et al., 2004). Available evidence suggests ac-
tivation of hepatic nuclear receptors by triclosan, with sub-
sequent upregulation of hepatic metabolism, which contributes
to the maintenance of thyroid homeostasis (Capen, 1994;
DeVito et al. 1999; Hill et al., 1998).
The current work tested the hypothesis that triclosan
decreased serum T4 in vivo by upregulation of hepatic
catabolism and altered expression of cellular transport proteins.
A 4-day exposure weanling rat model was employed as this
protocol has been used to characterize thyroid-disrupting
chemicals (Craft et al., 2002; Crofton, 2004; Zhou et al.,
2001) and demonstrates triclosan-induced hypothyroxinemia
(Crofton et al., 2007) and hepatic enzyme induction (Hanioka
et al., 1996). Serum total T4, T3, and TSH were measured.
Cytochrome P450 markers of phase I metabolism were
analyzed enzymatically and as mRNA expression levels by
quantitative reverse transcriptase (qRT)-PCR. Uridine diphos-
phate glucuronyltransferase (UGT) activity and the expression
of UGT and sulfotransferase (SULT) isoforms were also
measured as indicators of phase II catabolic pathways. Finally,
mRNA expression levels of several hepatic transporters were
measured to determine the contribution of hepatic transport to
the hypothesized mode of action for triclosan disruption of T4.
METHODS
Animals. Long-Evans female rats (n ¼ 120) at 21–23 days of age were
obtained from Charles River Laboratories, Inc. (Raleigh, NC) and were allowed
2–4 days of acclimation in an American Association for Accreditation of
Laboratory Animal Care–approved animal facility prior to treatment. Animals
were housed two per plastic hanging cage (45 3 24 3 20 cm) with heat-
sterilized pine shavings bedding (Northeastern Products Corp., Warrenton,
NC). Colony rooms were maintained at 21 ± 2C with 50 ± 10% humidity on
a photoperiod of 12L:12D (0600 h–1800 h). Food (Purina Rodent Chow
#5001) and water were provided ad libitum. Tap water (Durham, NC water)
was filtered through sand, then through activated charcoal, and finally
rechlorinated to 4–5 ppm Cl before use in the animal facility. All animal
procedures were approved in advance by the Institutional Animal Care and Use
Committee of the National Health and Environmental Effects Research
Laboratory of the U.S. Environmental Protection Agency (U.S. EPA).
The current work included hepatic tissue and serum samples from a previous
publication (Crofton et al., 2007) that reported only serum T4, body weight,
and liver weight values. The two experimental blocks from the previous study
(Crofton et al., 2007) were combined with the additional block performed in the
current study for T4 and hepatic enzyme assays; this yielded total sample sizes
of 24, 8, 24, 24, 24, and 16 for the vehicle control 10, 30, 100, 300, and 1000
mg/kg/day, respectively. Only samples for the second block (n ¼ 8/treatment
group) were used for mRNA analyses; therefore, no tissue from the 1000 mg/
kg/day group was used. Only samples for the third block were used for T3 and
TSH analyses (n ¼ 8/treatment group), so no tissue from the 10 mg/kg/day
group was used.
Chemicals and treatment. Triclosan (5-chloro-2-(2,4-dichlorophenoxy)-
phenol, CAS 3380-34-5, lot 06415CD) was obtained from Aldrich Chemical
Company (St Louis, MO; Cat 524190-10G). Mass spectrometry, employed to
analyze the triclosan sample, revealed 98.2% triclosan, 0.05% iso-triclosan,
0.12% 2,8-dichlorodibenzodioxin, and 0.1% 2,4,8-trichlorodibenzodioxin. The
dosing solutions (0, 10, 30, 100, 300, and 1000 mg/kg/day) were prepared in
corn oil (Sigma; lot 117K0127) and sonicated for 30 min at room temperature.
The 1000 mg/kg/day dose precipitated within 24 h and was therefore sonicated
daily before use. Dosing volume was 1.0 ml corn oil per kilogram body weight.
Rats (27–29 days of age) were exposed via gavage for four consecutive days.
Rats were randomly assigned to treatment groups to balance body weights at
the start of dosing. Body weights were recorded, and dosing volumes were
adjusted daily by weight. Approximately 24 h after the final treatment, rats
were moved into a holding room, weighed, and acclimated for a minimum of
30 min. Trunk blood and liver were collected between 0900 h and 1100 h in an
adjacent room with a separate air supply. Blood was collected into serum
separator tubes (Becton Dickinson; 36-6154). Serum was obtained after clotting
whole blood for 30 min on ice, followed by centrifugation at 12783 g at 4C
for 30 min. Livers were weighed and then quick frozen in liquid nitrogen.
Serum and liver samples were stored at 80C until analysis.
TH assays. Serum total T4 and serum total T3 were measured in duplicate
by standard solid-phase Coat-A-Count radioimmunoassay (RIA) kits (Siemens
Medical Solutions Diagnostics, Los Angeles, CA). Serum TSH concentrations
were analyzed in duplicates with a double antibody RIA method (Greenwood
et al., 1963) with some modification (Zorrilla et al., 2009). The TSH RIAs were
performed using materials supplied by the National Hormone and Pituitary
Agency: iodination preparation (I-9-TSH), reference preparation (RP-3), and
antisera (S-6-TSH). Iodination material was radiolabeled with 125I (Perkin Elmer,
Shelton, CT). Assay variation was assessed using the multivalent control module
(Siemens Medical Solutions Diagnostics; lot 021) to measure low, medium, and
high total T4, T3, and TSH values before and after measuring the experimental
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samples. Intra- and interassay coefficients of variance for all assays were below
13%. Total serum T4 and TSH were calculated as nanogram T4 per milliliter
serum, and total serum T3 was calculated as nanogram T3 per deciliter serum.
Microsome preparation and EROD and PROD assays. Liver microsomal
fractions, prepared as described previously (DeVito et al., 1993), were
standardized using total protein (Bio-Rad, Richmond, CA). Hepatic micro-
somal EROD and PROD activities were assayed using a fluorometric micro-
plate reader (Spectramax Gemini XPS; Molecular Devices/MDS Analytical
Technologies, Toronto, Canada). Each well in polystyrene 96-well plates (Nunc
Thermo Fisher Scientific, Rochester, NY) contained a total of 235 ll, including
50 ll of substrate (1.5nM ethoxyresorufin or pentoxyresorufin), 50 ll of diluted
microsomes, and 110 ll of 0.05mM Tris buffer (pH 8.0). Microsomes were
diluted 1:10 for samples and 1:100 for the positive control in order to maintain
data points within the linear region of the standard curve. An aliquot (25 ll) of
NADPH was added to initiate the reaction. The fluorescence signal was
measured every 33 s for 5 min at 37C after reaction initiation. The rate of
resorufin formation was estimated by calculating Vmax/min using a resorufin
standard curve to extrapolate resorufin concentrations in the reaction. A similar
method was used to measure hepatic microsomal PROD activity using
pentoxyresorufin as a substrate. Both EROD and PROD values were calculated
as picomoles resorufin per milligram protein per minute. A positive control,
composed of pooled microsomes from rats acutely exposed to 10 lg/kg 2,3,7,8-
tetrachlorodibenzo-p-dioxin or 300 mg/kg Aroclor, was used to facilitate
interassay comparison.
UGT activity assay. UGT activity for T4 was measured by the method of
Beetstra et al. (1991) as modified by Zhou et al. (2001). Detergent such as Brij
56 was not included due to the potential for increased basal T4 glucuronidation
(Craft et al., 2002). A positive control microsome pool, composed of micro-
somes from rats that received a single 10-lg/kg 2,3,7,8-tetrachlorodibenzo-
p-dioxin dose or a single 300 mg/kg Aroclor 1254 dose, was used during each
trial to enable interassay comparison.
mRNA preparation and analysis. Approximately 0.2 g of frozen tissue was
homogenized in 2 ml of TRI Reagent (Molecular Research Center, Cincinnati,
OH; Cat. TR 118). Total RNA was extracted as per the protocol provided by the
Molecular Research Center (Chomczynski & Sacchi, 1987). RNA extraction was
processed in duplicate. Protein, nucleic acid content, and approximate RNA
concentrations were estimated with a DU800 Beckman Coulter Spectropho-
tometer via measurement of absorbance at 260 and 280 nm for each sample.
Analysis of RNA integrity was performed using an Agilent RNA 6000 Nano Kit
and Bioanalyzer according to the instructions provided (Part Number: G2938-
90033). Samples used in qRT-PCR experiments were selected from duplicates
based on optimizing the 260/280 nm ratio to 2.0 (range 2.00–2.14). The average
28s/18s ratio for samples used was 2.2 (range 1.9–3), and the average assigned
RNA integrity number (RIN) was 9.4 of 10 (range 8.2–10).
Gene expression assays were performed using Taqman One-step RT-PCR
Master Mix Reagent Kits (Applied Biosystems, Foster City, CA; Cat. 4309169),
which include AmpliTaq Gold DNA Polymerase, dNTPs including dUTP,
passive reference, and optimized buffer components for both the reverse
transcriptase (RT) and the DNA polymerase reactions. Also included is the RT
enzyme mix, containing the MultiScribe Reverse Transcriptase and RNase
inhibitor. Taqman Gene Expression Assays (Applied Biosystems) were used to
test the mRNA expression of specific genes involved in hepatic catabolism and
TABLE 1








Endogenous reference Ribosomal protein S18 Rps18 3.2493 0.9494 103.1 Rn01428915_g1
Phase I markers Cytochrome P450, family 1, subfamily a,
polypeptide 1
Cyp1a1 3.6424 0.8690 88.2 Rn00487218_m1
Cytochrome P450, family 2, subfamily b,
polypeptide 2
Cyp2b1/2 3.1757 0.9680 106.4 Rn02783833_m1
Cytochrome P450, subfamily 3A,
polypeptide 1
Cyp3a1/23 3.4391 0.9790 95.3 Rn01640761_gH
Phase II markers UDP-glycosyltransferase 1 family,
polypeptide A1
Ugt1a1 3.3699 0.9529 98.0 Rn00754947_m1
UDP-glycosyltransferase 1 family,
polypeptide A6
Ugt1a6 3.4287 0.9535 95.7 Rn00756113_mH
UDP-glucuronosyltransferase 2 family,
member 5
Ugt2b5 3.2953 0.8786 101.1 Rn01777314_s1
Sulfotransferase family 1B, member 1 Sult1b1 3.2091 0.9143 104.9 Rn00673872_m1
Sulfotransferase family, cytosolic, 1C,
member 1
Sult1c1 3.2282 0.9747 104.1 Rn00581955_m1
Phase III markers Solute carrier organic anion transporter
family, member 1a1
Oatp1a1 or Oatp1 3.3182 1.0016 100.2 Rn00755148_m1
Solute carrier organic anion transporter
family, member 1a4
Oatp1a4 or Oatp2 3.0310 1.1376 113.8 Rn00756233_m1
ATP-binding cassette, subfamily C (CFTR/
multidrug resistance-associated protein),
member 2
Mrp2 3.3033 1.0078 100.8 Rn00563231_m1
ATP-binding cassette, subfamily B
(multidrug resistance transporter/
TAP), member 1B
Mdr1b 3.6001 0.8957 89.6 Rn00561753_m1
Note. The endogenous reference gene Rps18 was used to standardize all the gene expression assays. The slope presented is the slope value obtained from a plot
of the threshold CT (dRn) versus log[RNA concentration], and R-squared value is the square of the correlation coefficient of the line obtained by the plot (Applied
Biosystems Publication 127AP05-03).
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transport (Table 1). Each 20-ll reaction contained 900nM of the gene-specific
primer and 125 ng of RNA sample, except for Oatp1a4 and Mdr1b, which
contained 400 ng of RNA per reaction. The 96-well plates were maintained at
4C during pipetting using a thermocycler block. Samples were analyzed in
triplicate using the experimental probe and in triplicate using the endogenous
control gene on each plate. Samples positions were distributed across the plate
based on a semi-random design, where each plate contained the same number of
samples from a dose group, but the samples were randomly selected and assigned
to well positions within the plate. Following sample loading, plates were
centrifuged at 295 xg at 24C for 3 min before being placed in a Stratagene
MxPro3005P QPCR Detection System (Stratagene, Agilent Technologies, Cedar
Creek, TX). The thermal profile was as follows: RT reaction at 48C for 45 min,
an initial 10-min denaturation period at 95C, followed by 60 PCR cycles of 15-s
denaturation at 94C, and 1-min annealing and extension at 60C.
The amplification efficiencies for all the genes used in qRT-PCR
experiments were confirmed using pooled untreated control RNA extracted
from female rat liver. Amplification efficiency was calculated according to the
equation, efficiency ¼ (10(1/m)  1) 3 100, where m ¼ the slope of the plot of
threshold CT (dRn) versus log[RNA concentration] (Table 1) (Applied
Biosystems Publication 127AP05-03).
qRT-PCR data sets were analyzed using a relative quantification method
(2DDCT) to describe the change in expression of the target experimental gene
relative to an endogenous reference gene (Livak & Schmittgen, 2001). Choice of
an endogenous reference gene was based on constant gene expression across all the
dosing groups and tissue-specific amplification efficiency (Livak & Schmittgen,
2001). The endogenous reference gene, ribosomal protein S18 (Rps18), was
selected after determining the amplification efficiencies of multiple candidate genes
(Pohjanvirta et al., 2006), including glyceraldehyde-3-phosphate dehydrogenase,
b2 microglobulin, Rps18, and ribosomal protein13a. Choice of genes was
contingent upon two criteria: involvement of the isoform in TH metabolism and
transport in rats as well as regulation of the isoform by CAR and/or PXR.
Data analysis. All three study blocks with a combined 120 were analyzed
using a two-way ANOVA (SAS 9.1; SAS Institute, Cary, NC), with dose and block
as independent variables and T4, EROD activity, PROD activity, and UGT activity
as dependent variables. Significant treatment effects were followed by mean
contrast testing using Duncan’s New Multiple Range Test (p < 0.05). T4, UGT,
EROD, and PROD data were analyzed as mean percent of control in order to
normalize the data across the three study blocks. qRT-PCR data (block 2 only) were
analyzed using a two-way ANOVA, with dose and plate number as independent
variables and 2DDCT as the dependent variable. T3 and TSH data (block 3 only)
were analyzed using one-way ANOVA, with dose as the independent variable and
hormone as the dependent variable (SAS 9.1; SAS Institute). Raw data for all
endpoints measured are available in the Supplementary Table.
Benchmark dose (BMD) and lower-bound confidence limit (BMDL)
estimates were determined using U.S. EPA Benchmark Dose Software (BMDS
version 2.0.0.33) as previously described (Crofton et al., 2007; Zhou et al., 2001,
2002). BMD analyses were performed to further define dose-dependent effects
that are not discernible using only information on the statistically significant
effects found using ANOVA. Use of BMDs enables estimation of the dose at
which a specified effect or benchmark response (BMR) may occur. The BMR
was set at a 20% decrease for T4 and T3 data (Crofton et al., 2007; Zorrilla et al.,
2009), 50% for increases in hepatic PROD activity, and 20% for changes in
mRNA expression and UGT activity data (Schlecht et al., 2006). These BMRs
were selected based on previous use in the literature, a need to balance the
statistical and perceived biological significance of a change in the measured end
point, and known mechanistic relationships (e.g., UGT and T4) (EPA, 2000).
The BMDs were calculated from the model fits to the data. The BMDL (lower-
bound confidence limit) was calculated as the 95% lower confidence interval.
RESULTS
No clinical signs of toxicity were observed in the rats
following the 4 days of triclosan treatment. Effects on liver
weight and liver-body weight ratio were consistent with a
previously published 4-day triclosan exposure model (Crofton
et al., 2007). There was a main effect of dose [F(5, 105) ¼
2.57, p < 0.0309] and study block [F(2, 105) ¼ 6.24, p <
0.0027] on liver weight that resulted in a 12% increased liver
weight in the 1000 mg/kg/day dose group. Increases in liver
weight, and nonsignificant decreases in body weight gain
of ~10% in the high-dose group, were reflected in the main
effect of dose [F(5, 105) ¼ 18.62, p < 0.001] and study block
[F(5, 105) ¼ 3.50, p < 0.0338] on the liver-body weight ratio,
which resulted in approximately a 13% increase in the liver-
body weight ratio for the 1000 mg/kg/day dose group (Table 2).
Both total serum T4 and total serum T3 decreased in a dose-
responsive manner, with decreases of 26, 35, and 57% relative
to control at 100, 300, and 1000 mg/kg/day for T4 and
decreases of 12 and 25% at 300 and 1000 mg/kg/day for T3,
respectively (Fig. 1). TSH was unchanged. For T4, there was
a main effect of dose [F(5, 105) ¼ 37.46, p < 0.0001], but no
effect of study block (p < 0.05) or dose-by-study block
interaction (p < 0.05). Mean contrast tests revealed significant
T4 decreases in the 100-, 300-, and 1000 mg/kg/day groups
(p < 0.05). There was also a main effect of dose on T3
concentrations [F(4, 35) ¼ 12.80, p < 0.0001]; mean contrast
tests demonstrated significant decreases at 300 and 1000 mg/
kg/day only (p < 0.05). The no-observed effect level was 30
mg/kg/day for T4 decreases and 100 mg/kg/day for T3
decreases. Using a BMR equal to a 20% decrease in THs,
Hill model fits to the data predicted BMDs of 99.4 and 606 mg/
kg/day, with 95% lower confidence limits of 65.6 and 335 mg/
kg/day, for T4 and T3, respectively.
EROD activity was depressed by triclosan exposure in
a non–dose responsive manner (Fig. 2A), with a 25–32%
decrease for all dose groups except 10 mg/kg/day group. There
was a significant main effect of dose [F(5, 105) ¼ 7.34, p <
0.0001] but no main effect of study block (p < 0.05) or
TABLE 2
Doses, Group Sizes, and Block-Controlled Body Weight Gain,















0 24 100 ± 16 100 ± 9.3 100 ± 4.9
10 8 102 ± 12 104 ± 18 105 ± 4.1
30 24 108 ± 16 103 ± 11 102 ± 4.7
100 24 105 ± 14 101 ± 12 101 ± 4.7
300 24 105 ± 24 105 ± 13 104 ± 5.2
1000 16 92 ± 20 112 ± 12* 113 ± 4.9*
Note. Significant increases of nearly 12 and 13% occur in the 1000 mg/kg/
day dose group for liver weight and liver-to-body-weight ratio, respectively.
BW, body weight.
*Significantly different from vehicle control by ANOVA (p > 0.05).
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dose-by-study block interaction (p > 0.05). PROD activity was
significantly elevated in a dose-dependent manner (Fig. 2B).
The 100-, 300-, and 1000 mg/kg/day groups were increased by
249, 814, and 937% of control, respectively. These conclusions
are supported by main effects of dose [F(5, 104) ¼ 29.95, p <
0.0001] and a dose-by-study block interaction [F(7, 104) ¼
4.86, p < 0.0001]. The interaction of study block and dose
was due to a higher baseline activity in block 3 and a slightly
greater induction compared with study blocks 1 and 2. Note
that there was significant induction of PROD in all three study
blocks. Mean contrast tests revealed significant effects in the
300 and 1000 mg/kg/day groups (p < 0.05). Using a BMR
equivalent to a 50% increase in PROD activity, a Hill model fit
to the data predicted a BMD of 70.8 mg/kg/day, with a 95%
lower confidence limit of 48.6 mg/kg/day. The increased
EROD (22-fold) and PROD (3.5-fold) activities in the positive
control were consistent with laboratory historical control data.
Expression levels of hepatic microsomal CYP mRNA were
differentially altered by triclosan exposure (Fig. 3). There was
no significant effect of triclosan on relative mRNA expression
of Cyp1a1. Cyp2b1/2 and Cyp3a1/23 increased in a dose-
dependent manner. There were main effects of dose for both
Cyp2b1/2 [F(4, 35) ¼ 3.30, p < 0.0214] and Cyp3a1/23 [F(4,
35) ¼ 9.52, p < 0.0001]. Mean contrast tests revealed
significant increases of Cyp2b1/2 mRNA of twofold at 300
mg/kg/day only. Cyp3a1/23 was significantly increased 2.5-
fold and 4.1-fold in the 100 and 300 mg/kg/day groups,
respectively. Using a BMR equivalent to 20% increase in
mRNA expression, the BMD and BMDL for Cyp2b2 were
45.3 and 24.0 mg/kg/day and for Cyp3a1/23 were 62.3 and 7.3
mg/kg/day, respectively. The Cyp2b1/2 expression data were
best fit with a linear model, whereas the Hill model provided
the best fit for the Cyp3a1/23 expression data.
T4 glucuronidation activity increased with triclosan treat-
ment (Fig. 4). There were main effects of dose [F(5, 104) ¼
2.38, p < 0.0435] and block [F(2, 104) ¼ 5.20, p < 0.0070] but
no dose-by-study block interaction (p < 0.05). Mean contrast
testing revealed a significant 82% increase at 1000 mg/kg/day.
BMDS did not fit the data using linear, Hill, polynomial, or
exponential models.
Triclosan exposure induced isoform-specific increases in
UGT and SULT mRNA expression (Figs. 5 and 6). There was
a main effect of dose on Ugt1a1 mRNA expression [F(4, 35) ¼
5.98, p < 0.0009] but no significant effects on Ugt1a6 and
Ugt2b5. Mean contrast tests revealed significant 1.7-fold and
2.3-fold increases at 100 and 300 mg/kg/day, respectively.
Using a BMR equivalent to a 20% increase in mRNA expres-
sion, the BMD and BMDL were 22.7 and 6.4 mg/kg/day,
respectively. Triclosan increased Sult1c1 mRNA expression
[F(4, 35) ¼ 6.34, p < 0.0006] ~2.5-fold in the 100 and 300 mg/
kg/day groups (Fig. 6). The significant main effect of triclosan
on Sult1b1 mRNA expression [F(4, 34) ¼ 4.63, p < 0.0043]
was caused by small but significant decreases at 30 and
100 mg/kg/day (p < 0.05). Linear, Hill, polynomial, and
FIG. 1. Triclosan treatment results in dose-dependent decreases in total
serum T4 (A) and T3 (B), with no change in TSH (C), represented as group
mean values (± SE) percent of vehicle control for each study cohort V ¼
vehicle control, corn oil; for T4: n ¼ 24 for V, 30, 100, and 300 mg/kg/day
dose groups, n ¼ 16 for 1000 dose group, and n ¼ 8 for 10 dose group; for T3
and TSH: n ¼ 8 for V, 30, 100, 300, and 1000 mg/kg/day dose groups;
*significantly different from vehicle controls, p > 0.05.
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exponential models failed to significantly fit the mRNA
expression data for Sult1b1 and Sult1c1. Triclosan treatment
did not significantly alter mRNA expression of any of the
measured hepatic transporters: Oatp1a1 (Oatp1), Oatp1a4
(Oatp2), Mrp2, or Mdr1b (Fig. 7).
DISCUSSION
The current work tested the hypothesis that triclosan
decreased serum T4 via upregulation of hepatic catabolism
and altered expression of cellular transport proteins. Consistent
with this hypothesis, we report here that triclosan upregulates
both mRNA expression and activity of some phase I and phase
II hepatic enzymes. Contradictory to this hypothesis was the
lack of effects on any measured hepatic cellular transporters.
Furthermore, the pattern of effects on hepatic mRNA for CYP
and UGT isoforms suggests that the initiating event in the
mode of action for triclosan-induced hypothyroxinemia is
activation of hepatic CAR and PXR receptors.
Consistent with previous reports, oral exposure to triclosan
produced hypothyroxinemia. Dose-responsive T4 decreases
have been observed following both 4-day exposures (Crofton
et al., 2007) and 31-day exposures (Zorrilla et al., 2009). Ef-
fective doses that reduced T4 by 20% in the 4-day exposures
used in this work (BMD ¼ 99.4 mg/kg/day) were higher com-
pared with the smaller 4-day assay data set published previously
by this laboratory (BMD ¼ 69.7 mg/kg/day) (Crofton et al.,
2007). The effective dose that reduced T4 by 20% following
a 31-day triclosan exposure (BMD ¼ 14.5 mg/kg/day) was
much lower (Zorrilla et al., 2009) than those in the current study,
likely due to the differences in exposure duration as well as the
sex, age, and strain of rats used. Strain may be a particularly
important uncertainty in directly comparing studies of thyroid
disruption as background levels of THs and metabolic responses
may differ between strains (Lecureux et al., 2009).
T3 and TSH were also assessed to more fully characterize the
impact of triclosan on circulating thyroid and pituitary hor-
mones. The decreases (12–25%) in T3 observed at 300 and 1000
mg/kg/day were consistent with the previous reports that T3 was
decreased ~20% after 31 days of 200 mg/kg/day triclosan treat-
ment (Zorrilla et al., 2009). No change in TSH with triclosan
treatment is also consistent with a previous report (Zorrilla et al.,
2009). Other chemicals including polychlorinated biphenyls and
3-methylcholanthrene have significantly decreased T4 with no
effects on TSH (Hood et al., 1999; Liu et al., 1995); this
phenomenon of decreased T4 without compensatory TSH
increase, while not well understood, has been hypothesized to
result from a lack of induction of T3 glucuronidation (Barter &
Klaassen, 1994; Hood & Klaassen, 2000).
Triclosan exposure increased enzymatic and mRNA markers
of activity and expression of Cyp2b1/2 and Cyp3a1/23,
suggesting that triclosan may activate nuclear receptors CAR
and/or PXR. Increased PROD activity implies increased
Cyp2b1/2 protein. This is consistent with previous in vitro and
in vivo observations of triclosan-induced PROD activity and
Cyp2b1/2 protein (Hanioka et al., 1996, 1997; Jinno et al., 1997;
Zorrilla et al., 2009). Zorrilla et al. (2009) also found PROD
activity increases in vivo following 31-day exposures (BMD ¼
14.31 mg/kg/day) (Burke et al., 1994), compared with 70.8 mg/
kg/day, obtained in the present study. Relative mRNA
expression of Cyp2b1/2 and Cyp3a1/23 increased significantly.
This suggests that triclosan may be capable of interacting with
both CAR and PXR, consistent with activation of PXR in vitro
in a human (HuH7 culture) receptor reporter assay (Jacobs et al.,
2005). Currently, there are no published reports of triclosan
FIG. 2. Dose-effect curves for the effects of a 4-day exposure to triclosan on liver microsomal EROD activity (A) and PROD activity (B). Data are presented
as group mean (± SE) percent of vehicle control for each respective study block. Activity ¼ picomoles resorufin/mg protein/min; V ¼ vehicle control, corn oil;
PC ¼ positive control, single 10 lg/kg 2,3,7,8-tetrachlorodibenzo-p-dioxin dose and single 300 mg/kg Aroclor dose; n ¼ 24 for V, 30, 100, and 300 mg/kg/day
dose groups, n ¼ 16 for 1000 dose group, and n ¼ 8 for 10 dose group; *significantly different from vehicle control, p > 0.05.
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activity toward CAR. However, our observations of increased
Cyp2b1/2 activity and expression indicate potential CAR
activation (Qatanani et al., 2005; Sueyoshi et al., 1999).
EROD activity decreased slightly, and was not dose
responsive, corresponding well to the lack of significant
changes to Cyp1a1 mRNA expression; collectively, these data
imply that aryl hydrocarbon receptor (AhR) activation is not
a key step in this mode of action. No constitutive expression of
Cyp1a1 protein in rat liver and no induction of Cyp1a1 mRNA
with triclosan treatment suggest that these EROD decreases do
not reflect Cyp1a1 activity inhibition but rather the inhibition
of one or more of several CYPs, including Cyp2c11 (Burke
et al., 1994). Previous work with rat liver microsomes
demonstrated that triclosan competitively inhibited EROD
induction by 3-methylcholanthrene, a prototypical microsomal
enzyme inducer of EROD and Cyp1a1 activities (Hanioka
et al., 1996). However, the failure of triclosan to induce EROD
is inconsistent with a report of triclosan agonism of AhR;
triclosan activated AhR to 40% of the level of activation of
TCDD and inhibited TCDD activation by 30%, suggesting
a competitive interaction (Ahn et al., 2008).
Importantly, the lack of Cyp1a1 induction demonstrates that
the minor dioxin contaminates found in the triclosan sample
used in this study, 2,8,-dichlorodibenzodioxin and 2,4,8-
trichlorodibenzodioxin, did not induce AhR-mediated effects
on phase I and phase II hepatic enzymes. 2,8-dichlorodibenzo-
dioxin is a very weak AhR agonist in vitro and failed to induce
EROD in vivo (Mason & Safe, 1986).
Phase II glucuronidation and sulfation are upregulated by
triclosan treatment, suggesting that triclosan treatment in-
creases hepatic T4 conjugation. Observations of a twofold
FIG. 3. Dose-response curves for the effects of a 4-day exposure to
triclosan on liver mRNA expression of CYP isoforms. Data are plotted as the
mean (± SE) fold change (2DDCT) from control for the genes assayed: Cyp1a1
(A), Cyp2b2 (B), and Cyp3a1/23 (C). V ¼ vehicle control, corn oil; n ¼ 8 per
dose group; *significantly different from vehicle control, p > 0.05.
FIG. 4. Dose-effect curve for the effects of a 4-day exposure to triclosan on
liver microsomal UGT activity. Data are presented as group mean (± SE) percent
of vehicle control for each respective study block. UGT activity ¼ picomoles
T4-G/mg protein/min; V ¼ vehicle control, corn oil; PC ¼ positive control, single
10 lg/kg 2,3,7,8-tetrachlorodibenzo-p-dioxin dose and single 300 mg/kg Aroclor
dose; n ¼ 24 for V, 30, 100, and 300 mg/kg/day dose groups, n ¼ 16 for 1000
dose group, and n ¼ 8 for 10 dose group; *significantly different from vehicle
control, p > 0.05.
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increase in glucuronidation activity of T4 and a 2.2-fold
increase in Ugt1a1 mRNA expression suggest small increases
in T4-UGT activity result from triclosan exposure. Increases in
glucuronidation result in increased biliary excretion of con-
jugated hormone (Barter & Klaassen, 1994; Liu et al., 1995;
Vansell & Klaassen, 2001, 2002). Previous work in this
laboratory and others has found that UGT activity may
not have a clear linear relationship with T4 concentrations
(Craft et al., 2002; Hood & Klaassen, 2000). Another major
uncertainty regarding the testing of UGT isoforms for mRNA
expression levels is the choice of isoforms to test. This work
tested isoforms responsible for hepatic conjugation of T4 in rat,
Ugt1a1 and Ugt1a6 (Vansell & Klaassen, 2002), as well as
a marker of T3 glucuronidation, Ugt2b5 (Richardson et al.,
2008; Vansell & Klaassen, 2002). Whereas mRNA expression
of Ugt1a1 and Ugt1a6 can be found in the liver, Ugt1a7, which
also conjugates T4, appears to be constitutively expressed
mainly in the intestine of rats (Shelby et al., 2003) and
inducible in liver by AhR agonists (Metz et al., 2000). Thus,
Ugt1a7 was excluded from analysis as an amplification
efficiency in the appropriate range could not be determined
for analysis by qRT-PCR. No changes in expression were
observed for Ugt1a6 or Ugt2b5. In comparing the T4-UGT
activity and mRNA expression data, it appears likely that
the approximately twofold increase in T4-UGT activity
may be attributed to increases observed in Ugt1a1 mRNA
expression.
While increased activity and expression of UGT isoforms
support the overall hypothesis that triclosan treatment induces
glucuronidation of TH, these data do not confirm a particular
nuclear receptor pathway as CAR, PXR, and the glucocorticoid
receptor (GR) all transcriptionally regulate isoform Ugt1a1
(Sugatani et al., 2005). Ugt1a6 is more exclusively controlled
by the AhR (Auyeung et al., 2003); the lack of expression
change for Ugt1a6 complements the unchanged expression of
Cyp1a1 and EROD activity. This is consistent with the lack of
AhR activation by triclosan and the lack of an AhR con-
tribution to the end points measured in the current work.
Triclosan exposure increased sulfotransferase Sult1c1
mRNA expression 2.6-fold, indicating that increased sulfation
and biliary excretion of T4 may occur. Sulfation deactivates T4
and increases its biliary excretion via enhancement of inner
ring deiodination and blockage of outer ring deiodination for
reactivation (Kester et al., 2003). Triclosan noncompetitively
inhibits the in vitro human hepatic microsomal sulfation of
3-hydroxybenzo(a)pyrene (3-OH-BaP), bisphenol A (BPA),
p-nitrophenol, and acetaminophen with IC50 concentrations in
the low micromolar concentration range; competitive inhibition
of the glucuronidation of 3-OH-BaP, BPA, and acetaminophen
was also observed (Wang et al., 2004). Thus, triclosan may
exert an inhibitory action on SULT and UGT catabolic en-
zymes, affecting the overall activity profile of UGTs and
SULTs in vivo. An uncertainty in our analysis is choice of
sulfotransferases to test; sulfation of THs is catalyzed primarily
FIG. 5. Dose-response curves for the effects of a 4-day exposure to
triclosan on liver mRNA expression of UGT isoforms. Data are plotted as the
mean (± SE) fold change (2DDCT) from control for the genes assayed: Ugt1a1
(A), Ugt1a6 (B), and Ugt2b5 (C). V ¼ vehicle control, corn oil; n ¼ 8 per dose
group; *significantly different from vehicle control, p > 0.05.
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by Sult1b1 and Sult1c1 in the rat, although the preferred
substrate for these enzymes is actually not the physiologically
relevant TH (T3) but rather a T3 metabolite (T2) (Kester et al.,
2003). Any future use of these data in extrapolation to potential
human effects is complicated by the sex dependence of Sult1c1
expression in rats (Wong et al., 2005), which signals a
potentially sexually dimorphic response to triclosan with re-
spect to sulfotransferase expression changes. Male-dominant
expression of Sult1c1 reflects sex-dependent T3 sulfation in
rats, which is not known to occur in humans (Kaptein et al.,
1997). Our observations report mRNA expression changes in
female rats; however, the major change noted in sulfotrans-
ferases activity for triclosan treatment groups was upregulation
of Sult1c1, which is expressed predominantly in male rat liver,
kidney, and intestine; expression of Sult1b1 is equivalent bet-
ween rat sexes (Kester et al., 2003; Dunn and Klaassen, 1998).
No statistically significant changes were observed in the
mRNA expression of hepatic transporters, including Oatp1a1,
Oatp1a4, Mrp2, and Mdr1. These particular transporters were
chosen for analysis based on their functional activity and
affinity for iodothyronines (Wong et al., 2005) as well as
several previous literature reports of microsomal enzyme
inducer effects on these transporters (Cheng et al., 2005;
Johnson & Klaassen, 2002b; Klaassen & Slitt, 2005;
Kretschmer & Baldwin, 2005; Wong et al., 2005). These
mRNA expression results suggest that transporter expression
changes do not contribute to the observed T4 decreases.
However, these results do not exclude the possibility that
hepatic transporter protein activity is altered by triclosan
treatment via receptor-mediated posttranslational modifications
(Cherrington et al., 2002). The mRNA expression of Mrp2
may not be indicative of the in vivo protein expression as PXR
ligands that induce Cyp3a have been shown to increase Mrp2
protein without increasing Mrp2 expression (Johnson &
Klaassen, 2002a). Other PXR ligands, including DMP-904
(Wong et al., 2005), PCN, and spironolactone (Cheng et al.,
2005), and CAR ligands, including phenobarbital (Cherrington
et al., 2002), have previously demonstrated effects on the
regulation of hepatic transporter mRNA expression. Further
characterization of the hepatic transporter activity of the liver in
response to triclosan treatment will be necessary to conclude
definitively that transporters are or are not involved in
triclosan-induced hypothyroxinemia.
This work suggests that triclosan upregulates phase II
glucuronidation and sulfation and that this increased catabo-
lism may be at least partially responsible for the triclosan-
induced hypothyroxinemia observed. This is consistent with
other microsomal enzyme inducers including phenobarbital,
polychlorinated biphenyls, pregnenolone-16a-carbonitrile,
dioxins, and others (Liu et al., 1995; Schuur et al., 1998).
Correlation plots (data not shown) of T4 concentration versus
UGT activity and Ugt1a1 and Sult1c1 expression revealed
significant linear model fit (p < 0.05), but poor R-squared
values (R2 ¼ 0.07–0.18), suggesting that other mechanisms
contribute to the T4 decreases observed. Triclosan may exert
a direct effect on the thyroid and TH synthesis; however,
preliminary data in ex vivo porcine thyroid peroxidase assays
indicate no effect of triclosan (Hornung, personal communica-
tion). Other mechanisms that could contribute to the observed
hypothyroxinemia, including inhibition of iodide uptake,
competition with TH serum–binding proteins, and upregulation
of deiodinase activity, have not been assessed.
Extrapolation of the current findings to humans should be
tempered by a number of uncertainties, including the dose
range used herein versus estimated human exposures. The
BMDL for a 20% decrease in T4 calculated from the data pre-
sented is 65.6 mg/kg/day in a 4-day exposure scenario. This
short-term exposure model is intended for use as a tool in
exploring mechanisms of thyroid disruption and does not
model prolonged daily human exposure. The target human
FIG. 6. Dose-response curves for the effects of a 4-day exposure to triclosan on liver mRNA expression of SULT isoforms. Data are plotted as the mean (±
SE) fold change (2DDCT) from control for the genes assayed: Sult1b1 (A) and Sult1c1 (B). V ¼ vehicle control, corn oil; n ¼ 8 per dose group, with the exception
of n ¼ 7 for V dose group of Sult1b1; *significantly different from vehicle control, p > 0.05.
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population of interest due to the presence of triclosan in breast
milk and its potential to disrupt TH, and subsequent adverse
impacts on neurological development, is the developing
neonate and infant. Human infant daily oral exposure is
estimated to be 0.005 mg/kg/day (U.S. EPA, 2008). Thus,
comparing our BMDL to this daily intake yields a margin of
exposure of ~13,000-fold. Note that this does not take into
account uncertainty factors used in the extrapolation of data
obtained in rats to human risk; pharmacodynamic and phar-
macokinetic differences in triclosan metabolism between
species may greatly impact the relative effects.
The present work confirms the conclusion that triclosan
disrupts thyroxine and triiodothyronine in the rat. Furthermore,
the effects of triclosan on hepatic mRNA and enzymatic
activity point out important key events in one potential mode of
action of triclosan-induced hypothyroxinemia in rats and
suggest that CAR/PXR activation, with subsequent upregula-
tion of hepatic catabolism of T4, may be one mechanism that
contributes to the observed hypothyroxinemia. In order to
improve the ability to extrapolate these findings to humans,
future research should characterize interspecies similarities and
differences in these key events.
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